Lysylphenylalanyltyrosine

Lysylphenylalanyltyrosine

SCHEMBL4283566

NCCCCC(N)C(=O)NC(Cc1ccccc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 1/20 0.60
NPY2R P49146 1/20 0.60
NPY4R P50391 1/20 0.60
CHRNA1 P02708 1/20 0.56
CHRNG P07510 1/20 0.56
CHRNB1 P11230 1/20 0.56
CHRND Q07001 1/20 0.56
MME P08473 1/20 0.56
MMP2 P08253 1/20 0.56
OPRM1 P35372 4/20 0.54
ACE P12821 3/20 0.54
OPRD1 P41143 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30179482 1.00 NPY1R (0.60) NPY1RNPY2RNPY4RCHRNA1CHRNG
Lysylphenylalanyltyrosine SCHEMBL30179304 1.00 NPY1R (0.60) NPY1RNPY2RNPY4RCHRNA1CHRNG
Lysylphenylalanyltyrosine SCHEMBL4283579 1.00 NPY1R (0.60) NPY1RNPY2RNPY4RCHRNA1CHRNG
Lysylphenylalanyltyrosine SCHEMBL14583994 1.00 NPY1R (0.60) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL29577087 0.97 NPY4R (0.59) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL29576811 0.97 NPY4R (0.59) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL30179294 0.96 NPY4R (0.63) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL15011504 0.94 NPY4R (0.59) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL1373290 0.94 NPY4R (0.59) NPY1RNPY2RNPY4RCHRNA1CHRNG
SCHEMBL1373292 0.94 NPY4R (0.59) NPY1RNPY2RNPY4RCHRNA1CHRNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS NPY1R 2267/4885NPY2R 2027/4885NPY4R 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.